TrialDose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Trial details
- Registry ID
- NCT04219826
- Phase
- Phase 2
CYTK
Cytokinetics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
10Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Trial details
- Registry ID
- NCT04848506
- Phase
- Phase 2, Phase 3
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Trial details
- Registry ID
- NCT04944784
- Phase
- Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Trial details
- Registry ID
- NCT05186818
- Phase
- Phase 3
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Trial details
- Registry ID
- NCT05442775
- Phase
- Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Trial details
- Registry ID
- NCT05767346
- Phase
- Phase 3
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Trial details
- Registry ID
- NCT06081894
- Phase
- Phase 3
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Trial details
- Registry ID
- NCT06412666
- Phase
- Phase 2, Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Trial details
- Registry ID
- NCT06736574
- Phase
- Phase 3
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Trial details
- Registry ID
- NCT06793371
- Phase
- Phase 2
Latest recorded trial changes
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 · Cytokinetics
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Aug 2026
+ After
31 Aug 2026
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666 · Cytokinetics
Planned enrollment increased by 10 participants
− Before
55 participants (planned)
+ After
65 participants (planned)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 · Cytokinetics
Primary completion date changed
− Before
Jun 2026
+ After
Aug 2026
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346 · Cytokinetics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET)
+ After
Measure: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05186818 · Cytokinetics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET)
+ After
Measure: Change From Baseline in pVO2 at Week 24
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
NCT04219826 · Cytokinetics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Incidence of adverse events observed during dosing of CK--3773274 in patients with HCM
+ After
Measure: Incidence of Adverse Events (AEs) Measure: Incidence of Left Ventricular Ejection Fraction (LVEF) < 50% Measure: Incidence of Serious Adverse Events (SAEs)
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666 · Cytokinetics
Planned enrollment increased by 15 participants
− Before
40 participants (planned)
+ After
55 participants (planned)
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 · Cytokinetics
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting